title: [Peculiarities of lipid disorders in patients with type II diabetes mellitus: in which cases we should administer statins?].
abstract: Cardiovascular complications are a principal cause of death rate in the patients with type 2 diabetes, that in turn contribute to cardiovascular diseases and complications in adult population. According to UKPDS data high LDL Ch level is strong predictor of CHD development in patients with type 2 diabetes and its 1 mmol/l level increase, due the coronary risk increase on 57%. Patients with type 2 diabetes have the target levels of lipids enough rigid: the total Ch < 4.5 mmol/l, LDL Ch < 2.5 mmol/l, triglycerides < 1.7 mmol/l and HDL Ch > 1 mmol/l. The results of CARDS study have shown, that the treatment of the type 2 diabetes patients with mild hypercholesterolemia without CHD by atorvastatin in a doze of 10 mg during 5 years decreased cardiovascular risk on 37%, an stroke on 48% and the total death rate on 27%. In practice, 89% of the patients with type 2 diabetes comes to light deviations in Ch level. The lipid spectrum assay of should join to the obligatory diagnostic procedures in all type 2 diabetes patients despite of the age and sex. Statin therapy in the diabetes patients is as necessary as the antidiabetic treatment.
authors.forename: M N
authors.initials: MN
authors.lastname: Mamedov
mesh_terms: D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000453:epidemiology*; D011307:Drug Prescriptions; D050171:Dyslipidemias / Q000188:drug therapy* / Q000453:epidemiology*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D009626:Terminology as Topic; D016896:Treatment Outcome
chemical_list: D000924:Anticholesteremic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors